Petriĭ V V, Mikova N V, Makolkin V I
Kardiologiia. 2007;47(7):22-5.
Data of treatment of 45 patients with stable angina combined with type 2 diabetes mellitus are presented. Supplementation of standard anti-ischemic therapy with cytoprotective preparation trimetazidine MB (Preductal MB) revealed greater efficacy of treatment manifesting not only by decrease of functional class in observed patients but also by increase of volume of performed physical load, decrease of episodes of ischemia during 24 hours (according to Holter monitoring data), as well as decrease of mean duration of ischemia (painful and painless). A conclusion is made about feasibility of prescribing cytoprotective preparation trimetazidine MB while providing complex therapy to patients with stable form of ischemic heart disease.
本文展示了45例稳定型心绞痛合并2型糖尿病患者的治疗数据。在标准抗缺血治疗基础上加用细胞保护制剂曲美他嗪MB(Preductal MB),显示出更高的治疗效果,不仅表现为观察患者的心功能分级降低,还表现为运动负荷量增加、24小时内缺血发作次数减少(根据动态心电图监测数据)以及平均缺血持续时间(有痛和无痛)缩短。得出结论,在为稳定型缺血性心脏病患者提供综合治疗时,开具细胞保护制剂曲美他嗪MB是可行的。